Effect of BEMER Magnetic Field Therapy on the Level of Fatigue in Patients with Multiple Sclerosis: A Randomized, Double-Blind Controlled Trial

被引:33
|
作者
Piatkowski, Joachim [2 ]
Kern, Simone [1 ]
Ziemssen, Tjalf [1 ]
机构
[1] Tech Univ Dresden, MS Ctr Dresden, Dept Neurol, D-01307 Dresden, Germany
[2] Neurol Outpatient Ctr, Dresden, Germany
关键词
WEAK ELECTROMAGNETIC-FIELDS; DEFINITION; RESOLUTION; IMPACT;
D O I
10.1089/acm.2008.0501
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: Electromagnetic field therapy has been reported to be beneficial in patients with multiple sclerosis (MS) with significant fatigue. This study was designed to evaluate the long-term effects of Bio-Electro-Magnetic-Energy- Regulation (BEMER) on MS-related fatigue. Design: This was a monocenter, patient- and rater-blinded, placebo-controlled trial. Patients: There were 37 relapsing-remitting patients with MS with significant fatigue in the study. Intervention: The intervention consisted of BEMER magnetic field treatment for 8 minutes twice daily in comparison to placebo for 12 weeks. Outcome measures: The primary outcome criterion was change in the Modified Fatigue Impact Scale (MFIS) between baseline and 12 weeks. The secondary outcome criteria were changes of the Fatigue Severity Scale (FSS), a general depression scale-long version (ADS-L), Multiple Sclerosis Functional Scale (MSFC), and the Expanded Disability Status Scale (EDSS). Results: There was evidence of a significant difference of MFIS value (primary outcome criterion) after 12 weeks in favor of the verum group (26.84 versus 36.67; p = 0.024). In addition, FSS values were significantly lower in the verum group after 12 weeks (3.5 versus 4.7; p = 0.016). After 6 weeks' follow-up, verum and placebo groups did not differ in experienced fatigue (MFIS, FSS). Regarding the subscales of the MFIS, there was a significant decrease in physical (p = 0.018) and cognitive (p = 0.041), but not in psychologic subscales only in the verum group regarding the timepoints baseline and 12 weeks. BEMER therapy was well tolerated. Discussion: In this pilot study, we were able to demonstrate a beneficial effect of BEMER intervention on MS fatigue. As this was only a pilot study, trials with more patients and longer duration are mandatory to describe long-term effects.
引用
收藏
页码:507 / 511
页数:5
相关论文
共 50 条
  • [31] The effect of ginger (Zingiber officinale) supplementation on clinical, biochemical, and anthropometric parameters in patients with multiple sclerosis: a double-blind randomized controlled trial
    Foshati, Sahar
    Poursadeghfard, Maryam
    Heidari, Zahra
    Amani, Reza
    FOOD & FUNCTION, 2023, 14 (08) : 3701 - 3711
  • [32] DOUBLE-BLIND CONTROLLED TRIAL OF AZATHIOPRINE IN THE TREATMENT OF MULTIPLE-SCLEROSIS
    不详
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (10): : 1387 - 1387
  • [33] DOUBLE-BLIND, CONTROLLED TRIAL OF IMMUNOSUPPRESSION IN TREATMENT OF MULTIPLE-SCLEROSIS
    MERTIN, J
    KNIGHT, SC
    RUDGE, P
    THOMPSON, EJ
    HEALY, MJR
    LANCET, 1980, 2 (8201): : 949 - 951
  • [34] Therapeutic effect of co-administration of Amantadine and Aspirin on fatigue in patients with multiple sclerosis: a randomized placebo-controlled double-blind study
    Moghaddam, Akbar Hamzei
    Sedighi, Behnaz
    Iranmanesh, Farhad
    Abdi, Mohammad Hosein
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 683 - 683
  • [35] The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double-blind randomized controlled trial
    Foshati, Sahar
    Poursadeghfard, Maryam
    Heidari, Zahra
    Amani, Reza
    HEALTH SCIENCE REPORTS, 2023, 6 (01)
  • [36] GANGLIOSIDE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS - A DOUBLE-BLIND CONTROLLED TRIAL
    HARRINGTON, H
    HALLETT, M
    TYLER, HR
    NEUROLOGY, 1984, 34 (08) : 1083 - 1085
  • [37] Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
    Hawker, Kathleen
    O'Connor, Paul
    Freedman, Mark S.
    Calabresi, Peter A.
    Antel, Jack
    Simon, Jack
    Hauser, Stephen
    Waubant, Emmanuelle
    Vollmer, Timothy
    Panitch, Hillel
    Zhang, Jiameng
    Chin, Peter
    Smith, Craig H.
    ANNALS OF NEUROLOGY, 2009, 66 (04) : 460 - 471
  • [38] Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial
    Kouchaki, Ebrahim
    Tamtaji, Omid Reza
    Salami, Mahmoud
    Bahmani, Fereshteh
    Kakhaki, Reza Daneshvar
    Akbari, Elmira
    Tajabadi-Ebrahimi, Maryam
    Jafari, Parvaneh
    Asemi, Zatollah
    CLINICAL NUTRITION, 2017, 36 (05) : 1245 - 1249
  • [39] A double-blind pilot study of the effect of Prokarin™ on fatigue in multiple sclerosis
    Gillson, G
    Richards, TL
    Smith, RB
    Wright, JV
    MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (01) : 30 - 35
  • [40] Effect of whitening dentifrices: a double-blind randomized controlled trial
    Pintado-Palomino, Karen
    Matias Vasconcelos, Cecilia Vilela
    da Silva, Roberto Juns
    de Macedo Fressatti, Andre Luiz
    Goncalves da Motta, Bianka Jurca
    Panzeri Pires-De-Souza, Fernanda de Carvalho
    Tirapelli, Camila
    BRAZILIAN ORAL RESEARCH, 2016, 30 (01):